Gamma Knife System Market Size, Share, By Product Type (Head Gamma Knife System, and Body Gamma Knife System), Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation (AVM), Trigeminal Neuralgia, and Others), End User (Hospitals, Specialty Clinics, Radiotherapy Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Gamma knife system market size is expected to expand at a rate of USD 812.5 Million, by 2035.
• In 2024, the market valuation was USD 476.8 Million.
• Gamma knife system market is growing at a CAGR 5.4%.

The Gamma Knife system is a type of radiosurgery device that uses highly focused beams of gamma radiation to treat small targets in the head and brain, such as tumors or blood vessel defects. It's essentially a non-invasive alternative to traditional brain surgery, delivering a precise dose of radiation to the target while minimizing damage to surrounding healthy tissue.  It uses focused beams of radiation to treat brain tumors and other conditions without the need for incisions, reducing risks such as infection and bleeding. This method also allows for faster recovery times and often results in better long-term outcomes.

The rising prevalence of neurological disorders, such as, brain tumors, epilepsy, and others, increasing preference of patients and healthcare providers for minimally invasive treatment options due to shorter recovery times, reduced risks, and fewer complications compared to traditional surgery, and the non-invasive approach of gamma knifes are factors contributing in the gamma knife system market growth.

The development of new gamma knife system with improved precision and flexibility is enhancing the treatment capabilities, and Advances in treatment planning software allow for more accurate and personalized treatment plans, maximizing the effectiveness of Gamma Knife radiosurgery, are also factors driving the market expansion.

Impact of Generative AI on Gamma Knife System Market:

• By improving imaging, treatment planning, and post-treatment evaluation, generative AI is transforming the Gamma Knife systems. Algorithms powered by AI optimize dosage distribution, increasing accuracy and cutting down on planning time. Personalized therapies are made possible by deep learning algorithms, such GANs, which forecast 3D dosage distributions. 
• AI also makes it easier to create synthetic CT scans from MRI data, which reduces radiation exposure and streamlines procedures. These developments boost treatment effectiveness and expand the Gamma Knife's uses outside of cancer, which propels market expansion and uptake.

Key Drivers:

Rising Prevalence of Neurological Disorders is Skyrocketing the Market Expansion

Gamma knife system market is expanding due in large part to the increased incidence of neurological illnesses. Globally, more people are being diagnosed with diseases including trigeminal neuralgia, brain tumors, arteriovenous malformations, and functional disorders such as epilepsy.

For these problems, the Gamma Knife provides a highly accurate, non-invasive therapy alternative that minimizes harm to nearby healthy tissues. Gamma Knife systems are being more widely used in healthcare institutions as a result of the growing need for safe, efficient, and focused neurosurgical treatments as the world's population ages and becomes more susceptible to neurological problems.

• For instance, in March 2024, according to the data published by WHO, the most common cause of illness and impairment in the world today is neurological disorders. Access to treatment varies greatly; high-income nations have up to 70 times more neurological experts per 100,000 people than low- and middle-income countries, despite the fact that over 80% of neurological fatalities and health losses occur in these countries.

Restraints:

Limited Applicability of Gamma Knife System is Obstructing the Market Expansion

The restricted application of the gamma knife device to certain neurological diseases is one drawback of the market. It is not appropriate for treating bigger lesions, deeply embedded brain tumors, or conditions needing whole-brain therapy as it is primarily intended for intracranial targets. This limits further clinical acceptance by confining its usage to a certain patient population. Furthermore, not all patients with neurological problems are eligible for this treatment due to stringent eligibility requirements, which lessens its widespread appeal in neurosurgical and oncology offices.

• Counterbalance Statements: Treatment variety can be increased by developing Gamma Knife systems with AI-driven planning and conducting further research on adaptive radiation treatments. Expanding application will be facilitated by investigating novel clinical indications and using hybrid imaging technologies. Educating doctors on sophisticated procedures can also encourage broader, more efficient application of the technology in a variety of situations.

Opportunities & Trends:

Technological Advancements in Gamma Knife System is Fueling the Market Growth in the Future

Future gamma knife system market expansion is anticipated to be greatly aided by technological developments in gamma knife systems. More accuracy, quicker operations, and better patient outcomes are made possible by innovations including real-time imaging, improved treatment planning software, and integration with artificial intelligence. By providing frameless treatment options, newer devices such as the Gamma Knife Icon improve patient comfort and broaden eligibility.

AI-driven planning tools streamline workflows, reduce clinician burden, and enhance dose accuracy. Additionally, more individualized and efficient therapies are made possible by integration with cutting-edge imaging modalities such as CT and MRI. Hospitals find Gamma Knife systems more appealing as a result of these technical advancements, which increases market expansion and acceptance.

Gamma knife system market is segmented into product type, disease indication, end user, and region.

By Product Type:

According to product type, the market is bifurcated into head gamma knife system, and body gamma knife system. The head gamma knife system is the dominating product type of the gamma knife system market share. This is due to the widespread use of gamma knife for treating neurological disorders and brain tumors.

The body gamma knife is the second dominating product type of the Gamma knife system market. This is due to its advanced technology, increased precision, and ability to treat a wider range of conditions beyond the head, such as tumors and vascular malformations in other parts of the body.

By Disease Indication:

On the basis of disease indication, the market is pigeonholed into brain metastasis, cancer, arteriovenous malformation (AVM), trigeminal neuralgia, and others. The brain metastasis is the leading disease indication of the gamma knife system market share. This is due to the increasing use of Gamma Knife for treating brain metastasis, as it's a highly effective non-surgical option for managing these lesions.

The trigeminal neuralgia is the second leading disease indication in the gamma knife system market. This is due to gamma knife's effectiveness in treating this painful condition, especially when medication is ineffective. The procedure provides precise radiation delivery to the trigeminal nerve, offering significant pain relief with a low risk of complications compared to other surgical options.

 By End User:

Hospitals, specialty clinics, radiotherapy centers, and others are end users of the market. Hospitals have the most gamma knife system market share since they have the multidisciplinary teams, infrastructure, and patient volumes needed to support expensive equipment and difficult neurosurgery operations.

The second-largest section consists of specialty clinics, which only provide neurosurgery or radiosurgery services. Patients seeking precise, non-invasive treatments are drawn to these clinics because they provide specialist care and quicker treatment durations.

Regional Insights:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Asia Pacific: This is the region which is anticipated to rule over the gamma knife system market share, by approximately 37.5%, in the recent years. This is due to a combination of factors, such as, this region’s significant burden of neurological disorders, such as brain tumors and other neurological conditions, many countries of this region are witnessing a surge in healthcare expenditures, availability of Gamma Knife facilities and the increasing number of centers offering this treatment, and the presence of key market players in this region. Moreover, availability of Gamma Knife facilities and the increasing number of centers offering this treatment.

• China Gamma Knife System Market Insights:

The gamma knife system market in China is the most superior market, in the recent years. This is due to factors, such as, this country’s growing medical tourism sector, increasing awareness of advanced neurosurgical procedures, and government investment in healthcare infrastructure. Additionally, China benefits from expanding health insurance coverage, increased government healthcare spending, and a rising cancer incidence, all of which contribute to the demand for Gamma Knife treatments. Moreover, China's rising middle class, coupled with increasing disposable income, is also contributing in its market growth.

North America: This is the region which has the gamma knife system market growing with the highest CAGR, during the forecast period, in the recent years. This is due to various factors, such as, this region’s well-established healthcare systems with a high concentration of specialized medical centers and hospitals, a significant number of neurological conditions, and a hub for medical device innovation, with ongoing research and development activities focused on improving Gamma Knife technology and treatment outcomes. Moreover, government policies in North America often support the use of Gamma Knife systems for treating specific conditions, encouraging adoption by healthcare providers.

• U.S. Gamma Knife System Market Insights:

The gamma knife system market in the U.S. is the fastest growing market, in the recent years, during the forecast period. This is due to a combination of factors, such as, this country’s robust healthcare system with leading medical centers and hospitals, significant investment in healthcare allows for the acquisition and maintenance of advanced medical equipment, advancements in gamma knife systems, such as integrated imaging and treatment planning software, high incidence of brain tumors and other neurological disorders, adequate reimbursement for Gamma Knife procedures, and ongoing research and development activities focused on improving Gamma Knife treatment outcomes.

Europe: The region which experiences significant amount of gamma knife system market growth, in the recent years, is Europe. This is due to a variety of factors, such as, this region’s well-developed healthcare infrastructures, supportive government initiatives and reimbursement policies for non-invasive procedures, a growing preference for minimally invasive and highly accurate procedures with minimal damage to surrounding brain tissue, increasing prevalence of neurological conditions, and the increased healthcare spending.

• Germany Gamma Knife System Market Insights:

The gamma knife system market in Germany is experiencing considerate amount of growth, in the recent years. This is due to this country’s heavy investment in research and development, advanced healthcare system and supportive government initiative, a strong demand for minimally invasive and highly precise procedures, a strong demand for minimally invasive and highly precise procedures, and collaboration between medical institutions and research organizations.

Gamma Knife System Market Report Scope:

Attribute	Details
Market Size 2025	USD 505 Million
Projected Market Size 2035	USD 812.5 Million
CAGR Growth Rate	5.0% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Million & CAGR from 2025 to 2035
Regional scope	North America - U.S. and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India, Japan, Australia, Indonesia, Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Product Type:

• Head Gamma Knife System
• Body Gamma Knife System

By Disease Indication:

• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

By End User:

• Hospitals
• Specialty Clinics
• Radiotherapy Centers
• Others

 By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the market include, Elekta, Accuray Incorporated, Varian, and others. These key players are focusing on strategies such as, strategic alliances, research and development, mergers and acquisitions, and expanding clinical indications. These strategies aim to improve treatment efficacy, increase market reach, and capitalize on emerging opportunities, for driving Gamma Knife System Market growth.

Gamma Knife System Market Companies:

• Elekta
• Varian
• GE HealthCare
• Brainlab
• Akesis, Inc.
• ACIBADEM HEALTHCARE SERVICES
• ECU Health
• Fortis Healthcare
• Masep Medical Science & Technology Development Co., Ltd.
• Sotera Health

View an Additional List of Companies in the Gamma Knife System Market

• In June 2024, the first Gamma Knife Esprit in South Asia was proudly launched by Fortis Memorial Research Institute. A new age in non-surgical high precision brain tumor therapy was ushered in by this innovative Leksell Gamma Knife, which significantly expanded therapeutic choices for benign and malignant brain tumors and other brain disorders.
• In April 2024, The Elekta Esprit Gamma Knife was initially used to treat brain patients in Central Florida at the AdventHealth Neuroscience Institute. This sophisticated stereotactic radiosurgery (SRS) technology spares nearby healthy brain tissue while precisely delivering ablative radiation to specific brain targets. With a minimally intrusive technique, the new Gamma Knife platform can treat a range of benign and malignant illnesses.
• In October 2022, Elekta announced the FDA's 510(k) approval of Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform. This milestone opened the door to other nations where FDA approval was acknowledged and made the system accessible to professionals and individuals with brain disorders in the United States.
• In May 2022, with the introduction of Elekta Esprit, Elekta significantly advanced radiosurgery. In addition to more individualized and patient-friendly therapies, this most recent and sophisticated technology would provide physicians with far faster automated treatment planning, and a level of accuracy capable of safeguarding the individual and the mind.

Analyst View:

The gamma knife system market is growing due to a number of factors, including the increasing prevalence of neurological disorders such as brain tumors, epilepsy, and others; patients' and healthcare professionals' growing preference for minimally invasive treatment options as it is less risky, require less recovery time, and have fewer complications than traditional surgery; and the non-invasive nature of gamma knives.

The market is expanding due to the development of new Gamma Knife systems with increased precision and flexibility, which are improving treatment capabilities. Additionally, improvements in treatment planning software enable more precise and customized treatment plans, which maximize the effectiveness of Gamma Knife radiosurgery.

More Related Reports

Deep Brain Stimulation Systems Market
Gamma Knife Market
Deep Brain Stimulation Systems Market
Brain Implants Market
Brain Implants Market

Company Name	Elekta
Headquarter	Stockholm, Sweden
CEO	Mr. Gustaf Salford
Employee Count (2024)	4718 Employees